Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kura Oncology, Inc. (KURA : NSDQ)

• Company Description    Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. Number of Employees: 192

• Price / Volume Information    Yesterday's Closing Price: $5.60 Daily Weekly Monthly 20 Day Moving Average: 1,241,743 shares Shares Outstanding: 86.57 (millions) Market Capitalization: $484.82 (millions) Beta: 0.40 52 Week High: $23.48 52 Week Low: $5.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.77% -15.98% 12 Week -0.36% -19.89% Year To Date -35.71% -38.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12730 HIGH BLUFF DRIVE SUITE 400 - SAN DIEGO,CA 92130 USA ph: 858-500-8800 fax: - ir@kuraoncology.com http://www.kuraoncology.com

• General Corporate Information    Officers Troy E. Wilson - President and Chief Executive Officer Thomas Doyle - Senior Vice President Helen Collins - Director Faheem Hasnain - Director Thomas Malley - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 50127T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 86.57 Most Recent Split Date: (:1) Beta: 0.40 Market Capitalization: $484.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 22.23% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -11.86% vs. Previous Quarter: -200.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -73.82% ROE 06/30/25 - - 03/31/25 - -43.62 12/31/24 - -38.48 ROA 06/30/25 - - 03/31/25 - -29.13 12/31/24 - -30.15 Current Ratio 06/30/25 - - 03/31/25 - 8.07 12/31/24 - 9.46 Quick Ratio 06/30/25 - - 03/31/25 - 8.07 12/31/24 - 9.46 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -264.22 12/31/24 - -319.14 Book Value 06/30/25 - - 03/31/25 - 4.21 12/31/24 - 5.32 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.02 12/31/24 - 0.02 Debt-to-Capital 06/30/25 - - 03/31/25 - 2.06 12/31/24 - 1.64

Powered by Zacks Investment Research ©